Biologics : The work horses
Overview
Biologics: Empowering agile, small to mid-sized pharma companies to deliver enduring value with limited resources.
Biologics: The Workhorses of Small to Mid-Size Pharma Companies
In the rapidly evolving pharmaceutical landscape, biologics have emerged as a pivotal force, particularly for small to mid-size pharma companies. These companies are characterized by their agility, enabling them to swiftly navigate the complex terrain of drug development. Despite their limited reach and capital, these companies are poised to yield long-term value through their innovative approaches to creating Monoclonal Antibodies (MABs) and Novel Inhibitors (NIBs).
MABs and NIBs
At Atticus Healthcare, we have conducted comprehensive case studies to map the production and targeting of MABs and NIBs across 45 small to mid-size pharmaceutical companies. Here, we delve into the key findings and trends within this sector.
MABs: An Overview
The landscape of Monoclonal Antibodies (MABs) was meticulously charted to visualize their distribution by region and therapeutic indicators. Our study revealed that Non-Small Cell Lung Cancer (NSCLC) and Lymphoma are the primary focus areas for most MABs. This targeted approach reflects the pressing need for innovative treatments in these high-impact diseases.
Regional and Indicator-Based Distribution
% Drugs as MAB & Non MAB
Drugs by top 15 companies
NIBs: An Overview
Similarly, the landscape of Novel Inhibitors (NIBs) was charted, revealing that NSCLC and Hepatocellular Carcinoma are the main targets for these therapies. This focus underscores the critical need for new treatments in these challenging disease areas.
Regional and Indicator-Based Distribution
% Drugs as NIB & Non NIB
Drugs by top 15 companies
Company Mapping: MABs
Our study further delved into which specific companies, out of the 45 surveyed, are developing specific MABs. Remarkably, approximately 80% of all companies focus on producing 5-6 core MABs. However, the remaining 15+ MABs are being developed by only a handful of companies, indicating a specialized niche within the sector.
Key Insights
Company Mapping: NIBs
The distribution of NIB production among the 45 companies showed that roughly 80% of the companies are responsible for approximately 90% of all NIBs. This concentration indicates a lack of distinct gaps in the market, suggesting a comprehensive approach to NIB development within these companies.
Key Insights
Conclusion
The study by Atticus Healthcare provides a detailed snapshot of the MAB and NIB landscapes, highlighting the strategic priorities and regional strengths within small to mid-size pharmaceutical companies. By focusing on high-impact diseases such as NSCLC, Lymphoma, and Hepatocellular Carcinoma, these companies are poised to deliver significant long-term value despite their limited reach and capital. As the pharmaceutical industry continues to evolve, the role of biologics as workhorses for innovation and therapeutic advancement remains undeniable.
Make An Appointment Today
We have an excellent team to give you the best service of caregiving and take care of your loved ones. If you want to explore more about us and give us a chance to get you our finest service, book an appointment today and become a part of our community.
